Allergan Breast Implant Mass Tort Case Leads
Connect with patients diagnosed with BIA-ALCL or facing explant surgery after receiving recalled Allergan BIOCELL textured breast implants.
Allergan BIOCELL Textured Breast Implant Litigation
Allergan recalled its BIOCELL textured breast implants and tissue expanders worldwide in July 2019 at the FDA's request, after the agency linked the textured surface to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) — a cancer of the immune system that develops in the scar capsule around the implant. Lawsuits allege Allergan knew of the elevated risk, failed to warn patients and surgeons, and inadequately monitored adverse events. Federal claims are consolidated in MDL 2921 before Judge Brian R. Martinotti in the District of New Jersey, with roughly 1,300 cases pending as of July 2026. The docket is in active discovery, a qualified settlement fund and administrators have been appointed, and the first bellwether trial covering explant claims is set for October 19, 2026 — no global settlement has been announced.
Associated Conditions
- BIA-ALCL (breast implant-associated anaplastic large cell lymphoma)
- Persistent seroma or fluid collection around the implant
- Capsular contracture and hardening of the scar capsule
- Breast swelling, asymmetry, or a palpable mass
- Skin rash or lesions over the implant site
- Lymph node swelling near the chest or underarm
- Explant, capsulectomy, or revision surgery
Claimant Eligibility
- Received Allergan BIOCELL textured breast implants or tissue expanders (recalled July 2019)
- Diagnosed with BIA-ALCL, or underwent explant/capsulectomy surgery tied to the recall
- Operative reports or implant cards identifying the manufacturer, style, and lot number
- Pathology confirming lymphoma where a BIA-ALCL claim is asserted
- Claim filed within the applicable state statute of limitations
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Allergan Breast Implant legal marketing campaigns: how we acquire cases
Allergan Breast Implant case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Running a Allergan Breast Implant mass tort marketing campaign
Common questions from law firms about Allergan Breast Implant lawsuit lead generation and campaign management.
- What does a Allergan Breast Implant mass tort marketing campaign include?
- A Allergan Breast Implant mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Allergan Breast Implant case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Allergan Breast Implant mass tort case leads?
- Allergan Breast Implant mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Allergan Breast Implant legal marketing campaigns cost?
- Allergan Breast Implant legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Allergan Breast Implant leads exclusive to my firm?
- Yes. Every Allergan Breast Implant lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Allergan Breast Implant claimants qualified before delivery?
- Each Allergan Breast Implant claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Allergan Breast Implant case acquisition program scale?
- A Allergan Breast Implant mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
- Do Allergan breast implant campaigns separate BIA-ALCL claims from explant-only claims?
- Yes. The two tracks carry very different case values and evidentiary requirements, so intake distinguishes them at the point of screening. BIA-ALCL files are qualified on pathology confirmation; explant and capsulectomy files are qualified on operative records and implant identification tied to the recalled BIOCELL product. Both are delivered with the track flagged so your intake team can route them correctly — your firm makes the final eligibility determination.
- How do campaigns confirm a claimant actually received a recalled BIOCELL implant?
- Manufacturer and product style are the threshold facts on this tort. Screening captures the implanting surgeon and facility, surgery date, and any implant card, and flags whether the claimant can obtain operative records identifying an Allergan BIOCELL textured device. Claimants who only recall having implants, with no path to product identification, are screened out before delivery.
Get Allergan Breast Implant campaign pricing on a 30-minute call
We will walk your Allergan Breast Implant case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.